Great Lakes Advisors LLC Takes $2.10 Million Position in IDEXX Laboratories, Inc. $IDXX

Great Lakes Advisors LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,991 shares of the company’s stock, valued at approximately $2,101,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Elyxium Wealth LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP lifted its stake in shares of IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after purchasing an additional 1,442,174 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $628,223,000. Finally, Wellington Management Group LLP raised its holdings in IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock valued at $527,162,000 after buying an additional 592,834 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 2.0%

IDXX stock opened at $556.93 on Friday. The company’s 50 day moving average price is $560.01 and its 200 day moving average price is $576.88. The firm has a market capitalization of $43.88 billion, a price-to-earnings ratio of 39.17, a PEG ratio of 2.91 and a beta of 1.54. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the firm earned $3.50 earnings per share. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IDXX shares. Citigroup lifted their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays dropped their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, UBS Group boosted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.